| Barchart Demo Center |
$7.71
+0.05 (+0.65%)
as of May 31, 2024
as of May 31, 2024
| Profile | |
|---|---|
| Ticker Symbol | ELYM |
| Exchange | NASDAQ |
| Contact Information |
2801 Centerville Road 1st Floor Wilmington, DE USA P: 877-354-3689 |
| CEO/President | Andrew Levin |
| Earnings at a Glance | ||||
|---|---|---|---|---|
| Earnings | 03/31/24 -0.06 |
12/31/23 -0.12 |
09/30/23 -0.15 |
06/30/23 -0.19 |
| Price Earnings Ratio | N/A | |||
| EPS Growth | N/A | |||
| Most Recent Earnings ($) | -0.06 | |||
| Annual EPS ($) | N/A | |||
| Business Summary | |
|---|---|
| Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain psychiatry epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE United Kingdom. | |
| Industry/Sector | SIC-2834 Pharmaceutical Preparations Medical - Drugs |